Sarepta Therapeutics - Company & Market Research Reports

Sarepta Therapeutics is a biopharmaceutical company that focuses on the development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD). It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

From
From
From
From
From
From
From
Muscular Dystrophy - Pipeline Review, H1 2018 - Product Thumbnail Image

Muscular Dystrophy - Pipeline Review, H1 2018

  • Drug Pipelines
  • 152 Pages
From
From
From
From
From
From
From
Dystrophin (DMD) - Pipeline Review, H1 2018 - Product Thumbnail Image

Dystrophin (DMD) - Pipeline Review, H1 2018

  • Drug Pipelines
  • 80 Pages
From
From
From
Loading Indicator
adroll